Radar · Oncology in Maryland
Best Oncology Companies in Maryland, United States
The 110 best Oncology companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Viela Bio.
By Riya SenguptaFinancials
110companies tracked
$3Bdisclosed funding
0unicorns
72have raised
FLIAR INTELLIGENCE · ONCOLOGY × MARYLAND
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
120kcombined LinkedIn audience
53%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Viela Bio Developer of biologics for treating severe inflammation and autoimmune diseases | $357M | 84 mo ago | 170 | 2017 | — | 242 patents Immunomodulatory antibody/scaffold therapeutics targeting CD40L, CD19, Ilt7 for autoimmune diseases | — |
| 2 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | 2019 | Victor Velculescu Founder and Board of Directors | 52 patents Non-invasive cancer detection and monitoring via cell‑free DNA fragmentation profiling | 1 job opening · 1 partnership · 3 awards |
| 3 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | 2007 | Patrick Lu President and CEO | 277 patents siRNA therapeutics and nanoparticle delivery systems for cancer and viral diseases | 1 launch |
| 4 | Personal Genome Provider of advanced technology solutions for cancer genome analysis | $252M | 64 mo ago | 109 | 2010 | — | 143 patents Patents concentrated in chemistry & materials | — |
| 5 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 29 mo ago | — | 2016 | Adrian Hill Co-Founder | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 6 | Arcellx Developer of T cell-mediated anti tumour therapy | $200M | 40 mo ago | 130 130 → 224 (+72%) | 2014 | David Hilbert Founder & Co-CEO | 112 patents Engineered D-domain polypeptides for multifunctional immune cell therapy applications | — |
| 7 | Clasp Therapeutics Developer of T cell therapeutics for the treatment of cancer | $150M | 27 mo ago | — | 2020 | Shibin Zhou Co-Founder | — | 1 award |
| 8 | MacroGenics Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 87 mo ago | 339 339 → 378 (+12%) | 2000 | Scott Koenig President and CEO | 1,258 patents Therapeutic antibodies and ADCs targeting immune checkpoints (PD‑1, CD3, ADAM9, B7‑H3). | — |
| 9 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | 2005 | — | — | — |
| 10 | Sensei Biotherapeutics Developer of immunotherapies for the treatment of cancer | $94M | 65 mo ago | 27 | 1999 | John Celebi Chief Executive Officer | 19 patents Immuno‑oncology antibodies and bispecifics targeting the VISTA checkpoint for cancer therapy | — |
| 11 | DEKA Biosciences Developer of therapeutics for cancer and inflammatory diseases | $76M | 40 mo ago | 30 | 2018 | Pavel Khrimian Co-founder & CBO | 104 patents Engineered IL-10 cytokine fusions to mitigate cytokine release syndrome in CAR‑T/bi‑specific immunotherapies | — |
| 12 | Georgiamune Developer of immunotherapeutics to treat cancer and autoimmune diseases | $75M | 34 mo ago | 14 14 → 30 (+114%) | 2019 | Samir Khleif Founder & CEO | 122 patents Patents concentrated in chemistry & materials | — |
| 13 | CASI Pharmaceuticals Developer of therapeutics for the treatment of cancer 60Product top 19%Funding top 26%Growth top 36%Innovation top 38% All 10 signals ▾Producttop 19% Fundingtop 26% Growthtop 36% Innovationtop 38% Fin. healthtop 43% Markettop 46% Moatbottom 49% Globalbottom 44% Newsbottom 41% Techbottom 33% Product: 3 distinct product lines · Company stage: Public Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | 5 mo ago | 234 | 1991 | — | — | — |
| 14 | Haystack Oncology Provider of personalized cancer diagnostic tests | $67M | 44 mo ago | 45 | 2021 | — | — | — |
| 15 | Gliknik Discovering and developing innovative biologics for immune disorders and cancers 22Funding top 21%Moat top 21%Product top 25%Patents top 31% All 9 signals ▾Fundingtop 21% Moattop 21% Producttop 25% Patentstop 31% Innovationtop 33% Globalbottom 36% Newsbottom 22% Marketbottom 20% Techbottom 16% Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $60M | 10 mo ago | 6 | 2007 | — | 246 patents Engineered multimeric Fc fusion proteins for enhanced complement activation and therapeutic antibodies | — |
| 16 | AsclepiX Therapeutics Developing anti-angiogenic therapeutics | $58M | 35 mo ago | 8 | 2011 | — | — | — |
| 17 | Dracen Developer of thaerapeutics for the treatment of cancers | $57M | 51 mo ago | 8 | 2017 | Thomas Estok CEO & President | — | — |
| 18 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 7 mo ago | 31 | 2008 | Jeff Galvin Chief Executive Officer | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 19 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 8 mo ago | 41 | 2020 | — | 128 patents Immune checkpoint antibody therapeutics, especially anti‑CTLA‑4 combos for cancer treatment | 1 job opening |
| 20 | Zyngenia Develops monoclonal antibody (mAb)-based drugs to treat cancer, inflammation and autoimmune disorders | $43M | 165 mo ago | 6 | 2008 | Carlos Barbas Founder | 37 patents Engineered multispecific peptide‑antibody complexes targeting EGFR and Ang‑2 for cancer therapy | — |
| 21 | VLP Therapeutics Developer of therapeutic vaccines for the treatment of cancer, infectious and CNS disease | $37M | 34 mo ago | 15 | 2012 | Wataru Akahata Co-Founder & CEO | — | — |
| 22 | NexImmune Developer of immunotherapeutics for cancer | $36M | 87 mo ago | 69 | 2011 | — | 92 patents Patents concentrated in health & consumer products | — |
| 23 | Mana Therapeutics Developer of therapies for the treatment of cancer | $35M | 54 mo ago | 9 | 2017 | Catherine Bollard Co-Founder | — | — |
| 24 | Rapafusyn Developer of therapeutics for treatment of multiple diseses | $28M | 9 mo ago | 3 | 2015 | Sean Hu CEO | — | — |
| 25 | Cellective Therapeutics Biotech research company working on B Cell Research for cancer and autoimmune diseases, acquired by MedImmune… | $28M | 260 mo ago | — | 2003 | Pascal Soriot CEO | — | — |
| 26 | Vaccinogen Exploring video game history, developers, and software providers | $17M | 127 mo ago | 24 24 → 12 (-50%) | 2007 | — | 6 patents Personalized autologous tumor antigen vaccines for cancer immunotherapy | — |
| 27 | Cytimmune Multifunctional and tumor-targeted cancer therapies | $15M | 65 mo ago | 1 | 1988 | Lawrence Tamarkin Co-Founder | — | — |
| 28 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 50 mo ago | 9 | 2016 | Dong Shen CEO | — | — |
| 29 | US Medical Innovations Developer of electrosurgery and plasma technology for the treatment of cancer | $11M | 45 mo ago | 29 | 2010 | — | — | 2 launchs |
| 30 | Benevir Innovative medicine, therapies, and medical technology for global healthcare solutions | $11M | 103 mo ago | 10 | 2011 | — | — | — |
| 31 | VerImmune Developer of vaccines for the treatment of cancer | $10M | 13 mo ago | 7 | 2019 | John Troyer Founder & COO | 36 patents Virus-like particle-based cancer immunotherapies that redirect antigen-specific immune responses | 1 award |
| 32 | Flavocure Biotech Developing next-generation oncology solutions inspired by nature for cancer treatment | $8M | 16 mo ago | — | 2014 | Henry Lowe Co-Founder | — | — |
| 33 | OS Therapies Developer of therapies for treating cancer | $8M | 3 mo ago | 5 | 2017 | Paul Romness CEO | 10 patents Ocular drug delivery formulations and handheld thermal devices for eye surface disorders | — |
| 34 | BioMarker Strategies Develops Cancer Diagnostics System | $7M | 104 mo ago | 8 | 2007 | Jerry Parrott President | 31 patents Predictive biomarkers and assays for enhancing immune checkpoint inhibitor cancer therapy | — |
| 35 | Theranostics Health Personalized medicine through proteomic-based diagnostics and therapeutics for improved healthcare | $7M | 129 mo ago | 5 | 2006 | Luis Gutierrez President & CEO | — | — |
| 36 | miRecule Developing microRNA therapies for the treatment of cancers | $5M | 9 mo ago | 8 | 2018 | Anthony Saleh Co-Founder & CEO | 52 patents Muscle‑targeted imaging agents and nucleic‑acid therapeutics for neuromuscular disorders | 1 award |
| 37 | OncoSTING Developer of immunotherapy for bladder cancer | $5M | 6 mo ago | 3 | 2018 | William Bill Bishai Co-Founder | — | — |
| 38 | Creatv Bio Developer of blood based tests for treating cancer | $4M | 81 mo ago | 9 | 2020 | — | — | — |
| 39 | Ibex Biosciences Developer of antibody and gene therapy technologies for oncology, inflammation, autoimmune disease and… | $4M | 16 mo ago | 11 | 2015 | — | — | — |
| 40 | Cellicure Developer of cell-based immunotherapies for cancer treatment | $4M | 49 mo ago | 3 | 2021 | Q Li Co-Founder & CEO | 6 patents Genetically engineered immune cell therapies (e.g., CAR‑T, modified lymphocytes) | — |
| 41 | Previse Provider of diagnostic tests for the detection of cancer | $3M | 32 mo ago | 10 | 2018 | Dan Lunz Co-Founder & CEO | — | — |
| 42 | Iyuda Therapeutics Developer of medicines for the treatment of multiple conditions | $3M | 3 mo ago | — | 2007 | William Sargent Jr. Founder & Chief Business Officer | — | — |
| 43 | Irazu Oncology Developer of vaccines for colorectal cancer patients | $3M | 30 mo ago | 2 | 2022 | Marco Chacon Founder | 5 patents Engineered Salmonella typhi live bacterial vectors for cancer antigen vaccine delivery. | — |
| 44 | Northwest Biotherapeutics Developer of dendritic cell-based vaccines for prostate and brain cancer | $2M | 18 mo ago | 22 | 1998 | — | 250 patents Dendritic cell-based cancer immunotherapies and checkpoint inhibitor combination treatments. | — |
| 45 | Cage Pharma Developer of drugs targeting the tumor metabolism | $2M | 25 mo ago | — | 2017 | Jeff Geschwind Founder | — | — |
| 46 | A&G Pharmaceutical Theranostics company developing targeted therapeutics and companion diagnostics for personalized cancer care | $2M | 16 mo ago | 12 | 2000 | Ginette Serrero Co - Founder & CEO & Board Director | — | — |
| 47 | Amplexd Therapeutics Developer of therapeutics to treat cervical cancer | $2M | 25 mo ago | — | 2022 | Reid von Borstel Co-Founder | — | — |
| 48 | Nanocan Developer of therapeutic solutions for cancer treatment | $1M | 14 mo ago | 5 | 2020 | Eric Broyles Founder & CEO | — | — |
| 49 | Shuttle Pharma Developer of therapies to improve outcome of radiation therapy in cancer suffering patients | $1M | 12 mo ago | 7 | 2012 | — | — | — |
| 50 | ImmunoBlue Developer of nanoimmunotherapies for cancer treatment using nanotechnology and immunotherapy | $400K | 21 mo ago | — | 2016 | Rohan Fernandes Founder and CEO | — | — |
Top 12 Oncology companies in Maryland
#1
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Series B · Baltimore, Maryland · founded 2019 · 197 employees
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Patents
top 24%AI
top 28%Moat
top 28%Innovation
top 32%Talent
top 42%Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Conventional Debt (Dec 2025)
Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
AI: Holds AI/ML patents (G06N-family CPC) · Product described with: artificial intelligence
Audience (LinkedIn): 20k LinkedIn followers — 16.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Data Scientist, Computational Biology
Activity (LinkedIn): 1 partnerships · 3 awards (incl. OSF HealthCare) announced in 12 mo
Funding rounds
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
Founders & team
Investors
Merck Global Health Innovation Fund, DFJ Growth, Lilly, Point72, Brown Advisory, Point Field Partners
#2
Public · Gaithersburg, Maryland · founded 2007 · 88 employees$267Mraised▾
Public · Gaithersburg, Maryland · founded 2007 · 88 employees
Developer of RNA-based therapeutics for the treatment of cancer and fibrosis disease. The company has proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, to develop drug candidate pipeline which include STP122G for cardiovascular disease treatment. It also, develops pipeline of drugs for cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Growth
top 28%Moat
top 35%Market
top 46%Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 · Latest publication 2026
Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
Innovation: 277 patents (top 8% of patent-holders) · 191 filings since 2022 vs 63 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 6.2% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Post IPO$17.7M
- Jul 2021Series E$105M
- Oct 2020Series D$105M
- Jul 2019Series C$25M
Founders & team
Investors
Maryland, Rich Yield Capital, Rotating Boulder Fund, NIH SBIR/STTR, Yuexiu Group, Sangel Biomedical Venture Capital
#3
Public · Rockville, Maryland · founded 1991 · 234 employees$69.5Mraised▾
Public · Rockville, Maryland · founded 1991 · 234 employees
Developer of therapeutics for the treatment of cancer. The company's pipeline includes ENMD-2076, a selective angiogenic kinase inhibitor, and 2ME2 for autoimmune disorders. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Product
top 19%Funding
top 26%Growth
top 36%Innovation
top 38%Fin. health
top 43%Market
top 46%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) · Last round Post IPO (Dec 2025)
Growth: Headcount 189 → 234 (+24%) across vintages · Revenue +99% YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Dec 2025Post IPO$5M
- Jun 2024Post IPO$15M
- Jan 2016Post IPO$10.3M
- Feb 2012Post IPO$10M
Investors
Accel, Emerging Technology Partners, IDG Capital, Aravis, Kleiner Perkins
Tech stack
AccessibeBluehostDudaHstsJqueryJquery Migrate
#4
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Series B · Rockville, Maryland · founded 2008 · 31 employees
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 24%Patents
top 31%Moat
top 35%Talent
top 35%Innovation
top 37%Growth
top 40%Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) · Last round Series B (Nov 2025)
Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 228 patents · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
Founders & team
Investors
NIH, Ride wave ventures, HHS, Gaingels, Alumni Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon SesAmazon Web ServicesBeaver BuilderCdnjs
#5
Public · Cambridge, Maryland · founded 2017 · 5 employees$8.4Mraised▾
Public · Cambridge, Maryland · founded 2017 · 5 employees
Developer of therapies for treating cancer. The lead candidate of the company acts on HER-2 a member of the human epidermal growth factor receptor such as HER/EGFR/ERB which is used to treat Osteosarcoma. Also, developing folate receptor-targeted TDC for ovarian, pancreatic, lung, and others.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Mar 2026Post IPO$2M
- Jan 2026Post IPO$3.5M
- Sep 2025Post IPO$3.8M
- Jun 2025Post IPO$4.2M
Founders & team
Investors
K20 Fund
Tech stack
AosApache Http ServerBootstrapCdnjsCivicthemeCloudflare
#6
Series C · Baltimore, Maryland · founded 2007 · 6 employees$60.3Mraised▾
Series C · Baltimore, Maryland · founded 2007 · 6 employees
Discovering and developing innovative biologics for immune disorders and cancers. The company focuses on modulating the immune system to create new treatment options for autoimmune diseases and cancers. They are advancing multiple drugs through clinical trials, including recombinant Fc fusion proteins designed to mimic or inhibit specific immune pathways. Their approach involves a team of talented scientists, board members, scientific advisors, and a network of global thought leaders. They aim to make a significant difference in the lives of individuals with immune disorders through innovative drug discovery and development. Their expertise lies in biologics, clinical trials, drug design, protein production, purification, and analysis, targeting autoimmune diseases and cancers.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 21%Moat
top 21%Product
top 25%Patents
top 31%Innovation
top 33%Global
bottom 36%Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) · Last round Series C (Aug 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents
Product: 5 distinct product lines · Company stage: Series C
Funding rounds
- Aug 2025Series C$11M
- Nov 2024Series C$5.3M
- Jul 2023Series C$5.4M
- Jun 2021Series C$11.5M
Investors
Brace Pharma Capital, Pfizer, First In Ventures, RDA Ventures, SAISO Partners, Garden Street Holdings
Tech stack
WordpressMysqlPhpYoast SeoApache Http ServerLightbox
#7
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Series B · Rockville, Maryland · founded 2020 · 41 employees
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 17%Innovation
top 21%Funding
top 28%Moat
top 33%Global
bottom 43%Market
bottom 42%Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 · Latest publication 2026
Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21
Funding: Raised $52.3M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (Oct 2025)
Audience (LinkedIn): 3k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Research Associate
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
Investors
HHS, HM Capital, 3E Bioventures Capital, Kaitai Capital Management, GBA Fund, HM Venture Partners
#8
Series B · Rockville, Maryland · founded 2005 · 51 employees$97.9Mraised▾
Series B · Rockville, Maryland · founded 2005 · 51 employees
Immunomic Therapeutics develops lysosomal-associated membrane protein-based vaccines for the treatment of allergy and cancer. The company has partnered with Astellas to develop vaccines for Japnese red cedar (Phase 1), peanut allergy (Phase 1). Its immunology pipeline includes AST-VAC1 to treat acute myeloid leukemia (AML) (Phase 2); LAMP-Vax + pp64 DC therapy for brain cancer (Phase 1); ATTAC-II clinical trial (Phase II), etc.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 24%Growth
top 28%Product
top 30%Innovation
top 34%Moat
top 39%Tech
bottom 44%Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) · Last round Series B (May 2025)
Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo
Product: 8 distinct product lines · Company stage: Series B
Audience (LinkedIn): 4k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- May 2025Series B$6.5M
- Jan 2024Series B$3M
- Jan 2021Series B$77.7M
- Jul 2018Series A$314.5K
Investors
SBIR, Defense.gov, HLB, NIH, Keiretsu Forum, LSGPA
Tech stack
Animate.CssApache Http ServerBootstrapCloudflareCloudflare Browser InsightsContact Form 7
#9
Series A · Baltimore, Maryland · founded 2015 · 3 employees$28Mraised▾
Series A · Baltimore, Maryland · founded 2015 · 3 employees
Developer of therapeutics for treatment of multiple diseses. It offers platform that screens libraries of hybrid macrocycles to discover lead compound rapafucin-FKBP complexes against novel and validated targets which include oncology, immunosuppression, ischemic reperfusion injury, and neurodegenerative diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Sep 2025Series A—
- Jun 2024Series A$28M
Founders & team
Investors
3E Bioventures Capital, Proxima Ventures, Lapam Capital, BioTrack Capital, Yonjin Capital
#10
Seed · Owings Mills, Maryland · founded 2007$2.8Mraised▾
Seed · Owings Mills, Maryland · founded 2007
Developer of medicines for the treatment of multiple conditions. The company specializes in research and development focuses on creating cutting-edge therapies to address unmet medical needs such as oncological, infectious, and other immuno diseases.
Funding rounds
- Mar 2026Seed$600K
- Oct 2024Seed$1.3M
- Aug 2023Seed$900K
Founders & team
#11
Funding Raised · Baltimore, Maryland · founded 2018 · 3 employees$5Mraised▾
Funding Raised · Baltimore, Maryland · founded 2018 · 3 employees
Developer of immunotherapy for bladder cancer. The lead candidate OS-101 is a STING agonist and BCG-based immunotherapy for bladder cancer that trigger proinflammatory innate immune responses against tumors.
Funding rounds
- Dec 2025Grant (prize money)$2.2M
- Jun 2024Grant (prize money)$270.2K
- Jun 2022Grant (prize money)$256K
- Sep 2021Grant (prize money)$2.2M
Founders & team
Investors
HHS
#12
Seed · Rockville, Maryland · founded 2018 · 8 employees$5.5Mraised▾
Seed · Rockville, Maryland · founded 2018 · 8 employees
Developing microRNA therapies for the treatment of cancers. The company's DREAmiR platform utilizes genomic data of patients to identify and develop disease-targeting therapeutics. The product pipeline includes MC-DX4 for Facioscapulohumeral Muscular Dystrophy (FSHD), and MC-30 for Head & Neck Squamous Cell Carcinoma (HNSCC)
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 partnerships · 1 awards (incl. Sanofi) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$3.1M
- Apr 2025Grant (prize money)$3.1M
- Sep 2024Grant (prize money)$863.7K
- Sep 2021Grant (prize money)$1.9M
Founders & team
Investors
Maryland Momentum Fund, NIH SBIR/STTR, Alexandria, Boutique Venture Partners, Pathway Bioventures, FSHD Society
Tech stack
CloudflareCloudflare Browser InsightsContact Form 7DiviGoogle AnalyticsGoogle Font Api
Funding & investor landscape
$3Btotal disclosed funding
71companies funded
335disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Victor Velculescu
Founder and Board of Directors · Delfi Diagnostics
Susan Tousi
CEO · Delfi Diagnostics
Patrick Lu
President and CEO · Sirnaomics
Jeff Galvin
Chief Executive Officer · American Gene
Paul Romness
CEO · OS Therapies
Sean Hu
CEO · Rapafusyn
William Sargent Jr.
Founder & Chief Business Officer · Iyuda Therapeutics
William Bill Bishai
Co-Founder · OncoSTING
Trinity Bivalacqua
Co-Founder · OncoSTING
Anthony Saleh
Co-Founder & CEO · miRecule
John Troyer
Founder & COO · VerImmune
Joshua Wang
Founder & CEO · VerImmune
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN MARYLAND · Health & Bio
How research on Oncology in Maryland is moving
A read on the academic research around Oncology in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 83 papers.
University of Maryland's cancer institutions dominantly research immune cell function and immunotherapy biomarkers, with an optimistic stance driven overwhelmingly by recent breakthrough and advancement findings.
83 papers · stance +0.57 · 36% breakthrough · 9% concern
top institutions
- University of Maryland, Baltimore56
- University of Maryland, College Park12
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center6
- Virginia–Maryland College of Veterinary Medicine5
- University of Maryland, Baltimore County4
leading researchers
Meredith Wetzel · Pushpa Dhilipkannah · Ashutosh Sachdeva · Daniel Bergman · Pratima Sinha · Suzanne Ostrand‐Rosenberg
prism intelligence · tone & topics
99% positive · 0% critical tone
PharmaceuticalsBiotechnologyMedical ResearchClinical TrialsHealthHealthcare
▲
Breakthroughs27 · 33%
▲ 12%→36% share
▲3.0× share momentum0 median citations96% since 2021mostly methods-led
Tumor microenvironment research is newly emerging as a breakthrough focus, with 11 papers appearing where none existed before.
rising sub-themes (early→recent)
- Cancer research1→7
Newly emergingTumor microenvironment 0→11 · Immune system 0→10 · Immunotherapy 0→5
Landmark Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy · 249 cites
◆
Advancements41 · 49%
▼ 75%→48% share
▼0.6× share momentum2 median citations85% since 2021mostly empirical
Immunotherapy advancements are newly emerging and dominant, jumping from zero to 17 papers as field-share fell 75%->48%.
rising sub-themes (early→recent)
- Immune system4→17
- Tumor microenvironment3→16
- Cancer research1→11
Newly emergingImmunotherapy 0→17 · Cancer immunotherapy 0→5 · Pancreatic cancer 0→4
Landmark Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer · 1,707 cites
▼
Concerns7 · 8%
▼ 12%→7% share
▼0.6× share momentum5 median citations71% since 2021mostly reviews
Cancer concern research is newly emerging, with Tumor microenvironment and Immune system concerns each rising from 2 to 3 papers.
rising sub-themes (early→recent)
- Immune system2→3
- Tumor microenvironment2→3
Newly emergingCancer 0→3
Landmark Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response · 260 cites
Common questions
How many Oncology companies are there in Maryland, United States?
Radar tracks 110 indexable Oncology companies headquartered in Maryland, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Maryland, United States?
The Oncology companies in Maryland, United States on this list have raised a combined $3B in disclosed equity funding across 71 funded companies.
Which is the highest-funded Oncology company in Maryland, United States?
Viela Bio is the highest-funded Oncology company in Maryland, United States, with $357.3M in disclosed equity funding.
How many Oncology companies in Maryland, United States are funded?
71 of the 110 Oncology companies in Maryland, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Maryland, United States?
None of the Oncology companies in Maryland, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Maryland, United States Oncology companies?
The most active investors in Maryland, United States Oncology companies on this list include HHS, Business Innovation Network, Alexandria, Catalio Capital Management, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.